Clinical Trials Logo

Prostate Cancer Recurrent clinical trials

View clinical trials related to Prostate Cancer Recurrent.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT05002465 No longer available - Prostate Cancer Clinical Trials

Clinical Use of 68Ga PSMA-11 PET/CT in Diagnosing, Staging and Restaging Prostate Cancer

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this protocol is to provide 68Ga Prostate Specific Membrane Antigen-11 (68Ga PSMA-11) for clinical use in the diagnosis, staging and restaging of prostate cancer using Positron Emission Tomography with Computed Tomography (PET/CT) prior to its full local Federal Drug Administration (FDA) approval. Extensive research has shown that 68Ga PSMA-11 PET/CT offers higher detection rate of metastatic disease in prostate cancer than the current standard of care usually used in staging and restaging prostate cancer.